|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.4350 - 0.5040|
|52 Week Range||0.3500 - 1.5100|
|Beta (5Y Monthly)||-0.61|
|PE Ratio (TTM)||2.61|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jun 15, 2016|
|1y Target Est||N/A|
The company's Suboxone has been among the main treatments for addiction through a growing epidemic of opioid abuse in the United States. A film variant of Suboxone has lost more than half its market share to cheaper rivals in the last year. Indivior's shares have also plunged, by nearly two-thirds in 2019, as it also battles a potentially crushing $3 billion fine for illegally marketing Suboxone.
Indivior PLC (LON: INDV) today announced that its full year 2019 press release is now available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.
UK drugmaker Indivior has warned it could fall to a loss this year as its expects litigation related to its Suboxone opioid addiction treatment to have a “material impact” on earnings. The group reported a net loss of $55m for the three months to December 31, compared with a profit of $24m in the same period a year earlier. Shaun Thaxter, chief executive, said in a statement that “2019 was a challenging year for Indivior”, adding that 2020 “is shaping up to be a pivotal year”.
It's not possible to invest over long periods without making some bad investments. But you have a problem if you face...
Indivior PLC (LON: INDV) today announced a new research collaboration with Virginia Tech extending the RECOVER (Remission from Chronic Opioid Use-Studying Environmental and Socio-Economic Factors on Recovery) Study ™. RECOVER is a multisite, non-interventional cohort study examining long-term recovery in individuals with moderate to severe opioid use disorder who received at least one dose of study treatment during the SUBLOCADE Phase 3 clinical trials (NCT02357901 and NCT02510014). ¹ The study design and participant characteristics of the RECOVER study can be found in Contemporary Clinical Trials.2 This study will be led by a team of researchers at the Fralin Biomedical Research Institute at Virginia Tech Carilion.
Indivior PLC (LON: INDV) announced today that new analysis from a 12-month investigation of monthly buprenorphine extended-release injections showed that study participants who were treated with SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use (CIII), demonstrated improved or maintained patient-centered outcomes across the following measures:
New York and other states have reached a $700 million settlement deal with Reckitt Benckiser over allegations that the drug distributor improperly marketed a drug to treat opioid addiction, New York Attorney General Letitia James said on Wednesday. The deal is a part of an up to $1.4 billion settlement agreed to in July to resolve U.S. state and federal claims that Reckitt Benckiser's former pharmaceuticals business Indivior, before it was spun out, carried out an illegal scheme to boost sales of opioid addiction treatment Suboxone.
Drugmaker Indivior Plc reported a 14% rise in quarterly profit on Wednesday, as its best-selling opioid addiction drug Suboxone lost market share to generic rivals at a slower pace than the company's previous modelling had expected. The maker of drugs that treat opioid addiction posted a pretax profit of $89 million in the second quarter ended June 30 from $78 million a year earlier. Revenue fell nearly 20% to $215 million in the quarter due to the expected decline in market share for Suboxone, but Indivior reaffirmed that it expects 2019 revenue to be between $670 million and $720 million.
The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents. Suboxone film is applied below a patient's tongue, where it dissolves to release two active ingredients, buprenorphine and naloxone.
A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents.
The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film. The deal came after Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.
Britain's Reckitt Benckiser will pay up to $1.4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior. Reckitt Benckiser (RB) said it had reached agreements with the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC) to resolve the investigation into a business that was wholly demerged from the company in 2014. The U.S. Justice Department had accused Indivior of illegally boosting prescriptions for the opioid addiction treatment, called Suboxone Film.
Last week Durect Corp (DRRX) reported financial results for their first quarter ending March 31st and provided a pipeline development update. The development update was extensive and included highly compelling results of the first 10 patients enrolled in the DUR-928 Phase 2a alcoholic hepatitis trial. Relative to the financials, total revenue of $4.1M included $2.6M in product sales, mostly related to ALZET mini pumps and LACTEL biodegradable polymer products, as well as $1.5M in collaborative revenue.
Perseris, launched in the United States in February, is approved by the FDA for the treatment of schizophrenia in adults. The drug delivers its active ingredient, risperidone, in an extended-release delivery system with no loading doses or oral supplementation recommended. Indivior, which gets most of its revenue from Suboxone in the United States, was indicted last month for illegal marketing of Suboxone in the U.S. and was fined $3 billion.